<DOC>
	<DOCNO>NCT02730741</DOCNO>
	<brief_summary>The mechanism diarrhoea metformin poorly know . Recent data indicate change gut flora might responsible intestinal disorder . The effect metformin gut flora extensively describe . It show therapeutic effect metformin depend microbiota . In agreement data , recent publication show metformin 's main site action human intestine . In light result , seem plausible metformin 's effect gut flora responsible therapeutic effect also undesirable digestive effect . In respect , Lactobacillus rhamnosus show anti-diarrhoeal effect ( approximately 50 % reduction diarrhoea ) contexts infection-caused dysbiosis post-antibiotic dysbiosis . Hypothesis : Taking account favourable effect intestinal dysbiosis-induced diarrhoea observe Lactobacillus rhamnosus , put forward hypothesis Lactobacillus rhamnosus Lcr35速 favourable effect metformin-induced diarrhoea .</brief_summary>
	<brief_title>Study Efficacy Tolerance Oral Treatment With Total Freeze-dried Culture Lcr Restituo速 Sachets ( Lactobacillus Rhamnosus Lcr35速 ) Intolerance Metformin ( Diarrhoea ) Patients With Diabetes Type 2</brief_title>
	<detailed_description>There diabetes pandemic : The number diabetes patient expect reach 500 million worldwide 2030 , 90 % suffer type 2 diabetes . Therapeutically , metformin remain recommended first-line treatment . However , common digestive effect molecule , concern 30 50 % patient , major obstacle prescription . The availability treatment prevent unwanted effect would optimise treatment million diabetes patient . This would represent considerable advantage term public health due expect reduction cardiovascular morbidity . The mechanisms diarrhoea metformin poorly know . Recent data indicate change gut flora might responsible intestinal disorder . Recent data indicate change gut flora might responsible intestinal disorder . The effect metformin gut flora extensively describe . It show therapeutic effect metformin depend microbiota . In agreement data , recent publication show metformin 's main site action human intestine . In light result , seem plausible metformin 's effect gut flora responsible therapeutic effect also undesirable digestive effect . In respect , Lactobacillus rhamnosus show anti-diarrhoeal effect ( approximately 50 % reduction diarrhoea ) contexts infection-caused dysbiosis post-antibiotic dysbiosis . Hypothesis : Taking account favourable effect intestinal dysbiosis-induced diarrhoea observe Lactobacillus rhamnosus , put forward hypothesis Lactobacillus rhamnosus Lcr35速 favourable effect metformin-induced diarrhoea .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diseaserelated Patients , metabolic perspective , could benefit metformin treatment , namely patient late available hemoglobin glycated ( HbA1c ) old 3 month , high suggest recommendation , low 9 % . Patients type 2 diabetes receive metformin treatment least 2 month , treat nonoptimal dose metformin , i.e . 1500 mg/day le , due history diarrhoeatype digestive intolerance report drug . Patients time enter study blood sugar selfmonitoring device . Patients whose kidney function , evaluate reference creatinine clearance calculate use Cockcroft formula , 45ml/min high . Cohortrelated : Patients age 18 75 year For woman childbearing age : negative urine pregnancy test , use contraceptive method deem effective investigator throughout trial Patient able speak read French , informed study , voluntarily sign Informed Consent Form Patient cover social security scheme Diseaserelated : Patient present cardinal sign diabetes Patients present chronic diarrhoea history chronic intestinal inflammatory disease present episode acute diarrhoea 10 day precede inclusion . Treatmentrelated : Patients present contraindication metformin treatment diarrhoeatype digestive intolerance manifestation . Patients treat Inhibitors dipeptidyl peptidase 4 ( DPPIV inhibitor ) . Patients present serious adverse event associate metformin prescription . Patients take orlistat precede month take antibiotic precede month . Patients take probiotic month precede inclusion visit . Patients take prebiotics 15 day precede inclusion visit . Patients allergy one active ingredient one excipients study product . Cohortrelated : Patient refer physician . Patient deem investigator unable participate study Patient unable comply constraint protocol . Patient whose metabolic condition justify initiation dose increase metformin treatment . History bariatric surgery . Patient immunodeficient , chronic viral infection hepatitis B C , human immunodeficiency virus ( HIV virus ) Patient pregnant , plan pregnancy , without contraception . Breastfeeding patient . Patient previous illness , accord investigator , likely interfere study result expose patient additional risk . Patient linguistically unable ( unable speak write French ) mentally unable understand sign Informed Consent Form . Patient deprive liberty order Courts civil authority subject guardianship order . Patient likely comply treatment . Patient unable contact case emergency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>diarrhoea</keyword>
	<keyword>metfomin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>microbiota</keyword>
</DOC>